ReviewFrontiers in medicine2026
The translational potential of m6A RNA methylation in DKD: emerging biomarkers for early detection and targeted therapies.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic Kidney Disease (DKD) is a primary cause of end-stage renal disease, characterized by podocyte dysfunction. While current clinical biomarkers including albuminuria and estimated glomerular filtration rate are foundational for diagnosis, they often function as lagging indicators and fail to detect early renal injury. Recently, N6-methyladenosine (m6A) RNA methylation has emerged as a key epitranscriptomic link between hyperglycemia and podocyte injury, offering a novel frontier for diagnostic biomarker discovery. This review shifts the traditional focus from basic molecular mechanisms to the preclinical translational potential of m6A regulators and their downstream targets as early detection tools. Current experimental evidence in cell and animal models indicates that the abnormal upregulation of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.